OTCMKTS:IPCIF

Intellipharmaceutics International (IPCIF) Stock Price, News & Analysis

$0.06
0.00 (0.00%)
(As of 04/24/2024 ET)
Today's Range
$0.06
$0.06
50-Day Range
$0.03
$0.14
52-Week Range
$0.00
$0.14
Volume
5 shs
Average Volume
8,183 shs
Market Capitalization
$1.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IPCIF stock logo

About Intellipharmaceutics International Stock (OTCMKTS:IPCIF)

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.

IPCIF Stock Price History

IPCIF Stock News Headlines

The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
Intellipharmaceutics International Inc. (IPCI.TO)
The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
IPCIF Intellipharmaceutics International Inc.
Intellipharmaceutics Announces Cease Trade Order
Intellipharmaceutics Announces Third Quarter 2022 Results
Intellipharmaceutics Announces Fiscal Year 2021 Results
Intellipharmaceutics Comments on Recent Trading Activity
See More Headlines
Receive IPCIF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellipharmaceutics International and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/16/2018
Today
4/24/2024
Next Earnings (Estimated)
6/03/2024
Fiscal Year End
11/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:IPCIF
Employees
11
Year Founded
N/A

Profitability

Net Income
$-2,890,000.00
Net Margins
-344.25%
Pretax Margin
-343.61%

Debt

Sales & Book Value

Annual Sales
$660,000.00
Book Value
($0.32) per share

Miscellaneous

Free Float
32,511,000
Market Cap
$1.99 million
Optionable
Not Optionable
Beta
1.07
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Isa Odidi MBA (Age 66)
    Ph.D., Co-Founder, Chairman of the Board, CEO & Co-Chief Scientific Officer
    Comp: $347.94k
  • Dr. Amina Odidi Ph.D. (Age 64)
    President, COO, Co-Chief Scientific Officer, Acting CFO & Executive Director
    Comp: $347.94k
  • Dr. Patrick N. Yat Ph.D. (Age 66)
    Vice-President of Chemistry & Analytical Services
    Comp: $119.93k
  • Fazayill Shaideen
    Controller

IPCIF Stock Analysis - Frequently Asked Questions

How have IPCIF shares performed in 2024?

Intellipharmaceutics International's stock was trading at $0.0642 at the start of the year. Since then, IPCIF stock has decreased by 6.5% and is now trading at $0.06.
View the best growth stocks for 2024 here
.

Are investors shorting Intellipharmaceutics International?

Intellipharmaceutics International saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 28,600 shares, an increase of 2,760.0% from the March 15th total of 1,000 shares. Based on an average trading volume of 24,100 shares, the days-to-cover ratio is presently 1.2 days.
View Intellipharmaceutics International's Short Interest
.

When is Intellipharmaceutics International's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, June 3rd 2024.
View our IPCIF earnings forecast
.

How were Intellipharmaceutics International's earnings last quarter?

Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) issued its quarterly earnings data on Monday, July, 16th. The company reported ($0.70) EPS for the quarter, hitting the consensus estimate of ($0.70). The business had revenue of $0.58 million for the quarter, compared to analysts' expectations of $0.90 million.

When did Intellipharmaceutics International's stock split?

Intellipharmaceutics International shares reverse split on the morning of Friday, September 14th 2018. The 1-10 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Intellipharmaceutics International?

Shares of IPCIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IPCIF) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners